These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 33051240)

  • 1. Dysregulated NF-κB-Dependent ICOSL Expression in Human Dendritic Cell Vaccines Impairs T-cell Responses in Patients with Melanoma.
    Maurer DM; Adamik J; Santos PM; Shi J; Shurin MR; Kirkwood JM; Storkus WJ; Butterfield LH
    Cancer Immunol Res; 2020 Dec; 8(12):1554-1567. PubMed ID: 33051240
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multiple antigen-engineered DC vaccines with or without IFNα to promote antitumor immunity in melanoma.
    Butterfield LH; Vujanovic L; Santos PM; Maurer DM; Gambotto A; Lohr J; Li C; Waldman J; Chandran U; Lin Y; Lin H; Tawbi HA; Tarhini AA; Kirkwood JM
    J Immunother Cancer; 2019 Apr; 7(1):113. PubMed ID: 31014399
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TriMix and tumor antigen mRNA electroporated dendritic cell vaccination plus ipilimumab: link between T-cell activation and clinical responses in advanced melanoma.
    De Keersmaecker B; Claerhout S; Carrasco J; Bar I; Corthals J; Wilgenhof S; Neyns B; Thielemans K
    J Immunother Cancer; 2020 Feb; 8(1):. PubMed ID: 32114500
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.
    Palucka AK; Ueno H; Connolly J; Kerneis-Norvell F; Blanck JP; Johnston DA; Fay J; Banchereau J
    J Immunother; 2006; 29(5):545-57. PubMed ID: 16971810
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The p50 subunit of NF-κB orchestrates dendritic cell lifespan and activation of adaptive immunity.
    Larghi P; Porta C; Riboldi E; Totaro MG; Carraro L; Orabona C; Sica A
    PLoS One; 2012; 7(9):e45279. PubMed ID: 23049782
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IL-12p70-producing patient DC vaccine elicits Tc1-polarized immunity.
    Carreno BM; Becker-Hapak M; Huang A; Chan M; Alyasiry A; Lie WR; Aft RL; Cornelius LA; Trinkaus KM; Linette GP
    J Clin Invest; 2013 Aug; 123(8):3383-94. PubMed ID: 23867552
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bypassing STAT3-mediated inhibition of the transcriptional regulator ID2 improves the antitumor efficacy of dendritic cells.
    Li HS; Liu C; Xiao Y; Chu F; Liang X; Peng W; Hu J; Neelapu SS; Sun SC; Hwu P; Watowich SS
    Sci Signal; 2016 Sep; 9(447):ra94. PubMed ID: 27678219
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adenovirus MART-1-engineered autologous dendritic cell vaccine for metastatic melanoma.
    Butterfield LH; Comin-Anduix B; Vujanovic L; Lee Y; Dissette VB; Yang JQ; Vu HT; Seja E; Oseguera DK; Potter DM; Glaspy JA; Economou JS; Ribas A
    J Immunother; 2008 Apr; 31(3):294-309. PubMed ID: 18317358
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Autologous melanoma vaccine induces antitumor and self-reactive immune responses that affect patient survival and depend on MHC class II expression on vaccine cells.
    Lotem M; Machlenkin A; Hamburger T; Nissan A; Kadouri L; Frankenburg S; Gimmon Z; Elias O; David IB; Kuznetz A; Shiloni E; Peretz T
    Clin Cancer Res; 2009 Aug; 15(15):4968-77. PubMed ID: 19602547
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic vaccination with an autologous mRNA electroporated dendritic cell vaccine in patients with advanced melanoma.
    Wilgenhof S; Van Nuffel AM; Corthals J; Heirman C; Tuyaerts S; Benteyn D; De Coninck A; Van Riet I; Verfaillie G; Vandeloo J; Bonehill A; Thielemans K; Neyns B
    J Immunother; 2011 Jun; 34(5):448-56. PubMed ID: 21577140
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vaccination with autologous dendritic cells pulsed with multiple tumor antigens for treatment of patients with malignant melanoma: results from a phase I/II trial.
    Trepiakas R; Berntsen A; Hadrup SR; Bjørn J; Geertsen PF; Straten PT; Andersen MH; Pedersen AE; Soleimani A; Lorentzen T; Johansen JS; Svane IM
    Cytotherapy; 2010 Oct; 12(6):721-34. PubMed ID: 20429791
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced CD40 and ICOSL expression on dendritic cells surface improve anti-tumor immune responses; effectiveness of mRNA/chitosan nanoparticles.
    Daneshmandi S; Pourfathollah AA; Forouzandeh-Moghaddam M
    Immunopharmacol Immunotoxicol; 2018 Oct; 40(5):375-386. PubMed ID: 30265161
    [No Abstract]   [Full Text] [Related]  

  • 13. Plasmacytoid dendritic cells support melanoma progression by promoting Th2 and regulatory immunity through OX40L and ICOSL.
    Aspord C; Leccia MT; Charles J; Plumas J
    Cancer Immunol Res; 2013 Dec; 1(6):402-15. PubMed ID: 24778133
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MHC-restricted phosphopeptide antigens: preclinical validation and first-in-humans clinical trial in participants with high-risk melanoma.
    Engelhard VH; Obeng RC; Cummings KL; Petroni GR; Ambakhutwala AL; Chianese-Bullock KA; Smith KT; Lulu A; Varhegyi N; Smolkin ME; Myers P; Mahoney KE; Shabanowitz J; Buettner N; Hall EH; Haden K; Cobbold M; Hunt DF; Weiss G; Gaughan E; Slingluff CL
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32385144
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intralymphatic dendritic cell vaccination induces tumor antigen-specific, skin-homing T lymphocytes.
    Grover A; Kim GJ; Lizée G; Tschoi M; Wang G; Wunderlich JR; Rosenberg SA; Hwang ST; Hwu P
    Clin Cancer Res; 2006 Oct; 12(19):5801-8. PubMed ID: 17020987
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effective cancer immunotherapy by natural mouse conventional type-1 dendritic cells bearing dead tumor antigen.
    Wculek SK; Amores-Iniesta J; Conde-Garrosa R; Khouili SC; Melero I; Sancho D
    J Immunother Cancer; 2019 Apr; 7(1):100. PubMed ID: 30961656
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impaired ICOSL in human myeloid dendritic cells promotes Th2 responses in patients with allergic rhinitis and asthma.
    Shen C; Hupin C; Froidure A; Detry B; Pilette C
    Clin Exp Allergy; 2014 Jun; 44(6):831-41. PubMed ID: 24661627
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Blood dendritic cells generated with Flt3 ligand and CD40 ligand prime CD8+ T cells efficiently in cancer patients.
    Davis ID; Chen Q; Morris L; Quirk J; Stanley M; Tavarnesi ML; Parente P; Cavicchiolo T; Hopkins W; Jackson H; Dimopoulos N; Tai TY; MacGregor D; Browning J; Svobodova S; Caron D; Maraskovsky E; Old LJ; Chen W; Cebon J
    J Immunother; 2006; 29(5):499-511. PubMed ID: 16971806
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized multicenter trial of the effects of melanoma-associated helper peptides and cyclophosphamide on the immunogenicity of a multipeptide melanoma vaccine.
    Slingluff CL; Petroni GR; Chianese-Bullock KA; Smolkin ME; Ross MI; Haas NB; von Mehren M; Grosh WW
    J Clin Oncol; 2011 Jul; 29(21):2924-32. PubMed ID: 21690475
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Toll-like receptor 4 gene polymorphism influences dendritic cell in vitro function and clinical outcomes in vaccinated melanoma patients.
    Tittarelli A; González FE; Pereda C; Mora G; Muñoz L; Saffie C; García T; Díaz D; Falcón C; Hermoso M; López MN; Salazar-Onfray F
    Cancer Immunol Immunother; 2012 Nov; 61(11):2067-77. PubMed ID: 22552381
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.